Multigene testing in localized prostate cancer

Ashley E. Ross

Research output: Contribution to journalArticle

Abstract

Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend "consideration" of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.

Original languageEnglish (US)
Pages (from-to)659-662
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
StatePublished - May 1 2016

Fingerprint

Prostatectomy
Prostatic Neoplasms
Radiotherapy
Prospective Studies
Guidelines
Neoplasm Metastasis
Therapeutics
Conservative Treatment

ASJC Scopus subject areas

  • Oncology

Cite this

Multigene testing in localized prostate cancer. / Ross, Ashley E.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, 01.05.2016, p. 659-662.

Research output: Contribution to journalArticle

@article{635bd80297e04237bfb611d829d55d15,
title = "Multigene testing in localized prostate cancer",
abstract = "Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend {"}consideration{"} of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.",
author = "Ross, {Ashley E.}",
year = "2016",
month = "5",
day = "1",
language = "English (US)",
volume = "14",
pages = "659--662",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",

}

TY - JOUR

T1 - Multigene testing in localized prostate cancer

AU - Ross, Ashley E.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend "consideration" of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.

AB - Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend "consideration" of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84995812448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995812448&partnerID=8YFLogxK

M3 - Article

C2 - 27226507

AN - SCOPUS:84995812448

VL - 14

SP - 659

EP - 662

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

ER -